Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
before dispensing
The study design was approved by the Ethics Committee of the first Affiliated Hospital of Sun Yat-Sen University ([2012]248)
Integration into existing workflows and a solution that solves an enterprise wide pain point are critical
Individuals who are overweight or obese (with a BMI of 25 or higher) or have one or more obesity-related conditions may be suitable candidates for GLP-1 therapy
Semaglutide (Ozempic) and tirzepatide (Mounjaro) are FDA-approved only for type 2 diabetes management, not for weight loss
US$ 29.44
US$ 28.06
US$ 21.36
US$ 23.84
